Camp4 Therapeutics reports positive Phase 1 SAD safety data for CMP-CPS-001, enables MAD dose escalation

Camp4 Therapeutics Corp

Phase 1 SAD portion completed: 48 healthy volunteers, 32 received CMP-CPS-001; no serious adverse events, no maximum tolerated dose reached.
All treatment-emergent adverse events were Grade 1 or 2; most common: headache (6), nausea (4).
Safety Review Committee approved dose escalation and initiation of MAD Cohort 3.
Cash runway into Q2 2026; upcoming milestones: MAD data 2H'25, SYNGAP1 GLP tox studies in '25.
Corporate slide deck highlights RAP platform, pipeline, and strategic collaboration; IPO completed October 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.